The data base below lists known point mutations and short deletions and additions in the factor IX gene, causing the bleeding disorder haemophilia B or Christmas disease (for reviews, see Brownlee 1988 , Giannelli 1989 , Thompson 1990 , Green et al 1991a These mutations result in a defective clotting factor EX-a glycoprotein of 415 amino acid residues normally present in plasma and an essential component of the clotting cascade. The disease is an X-linked inherited recessive disorder affecting 1 in about 30,000 males and only very rarely females.
The purpose of this database is to update last year's one (Giannelli et al, 1991) by collecting in an accessible, summary form, molecular data on the causative mutations of haemophilia B patients worldwide. It is not intended to replace primary publications although it does contain a significant amount of unpublished work. As in previous years, we have included repeat observations of the same mutation, as well as molecularly unique mutations. We have continued our database numbering system (Giannelli etal (1991) giving all patients a unique Patient Identity Number (PIN or ID number).
The factor IX gene lies on the long arm of the X chromosome at Xq27 and its entire sequence of 33 kb is known (Yoshitake et al, 1985) . It contains 8 exons (a-h) encoding 6 major domains of factor IX. These are: (1) exon a-a hydrophobic signal peptide which targets the protein for secretion from the hepatocyte into the blood stream. (2) exons b and c-a propeptide and gla domain,-the latter containing 12 7-carboxyglutamyl residues. This post-translational modification is required for the correct folding and calcium binding of factor IX. (3) exon d-a type B, or first epidermal growth factor-like domain, which shows homology to epidermal growth factor (EGF) and, in addition, contains conserved carboxylate residues including a j3-hydroxyaspartate at amino acid 64. This domain binds an additional Ca 2+ with high affinity (Handford et al, 1991) . (4) exon e-a type A, or second epidermal growth factor-like (EGF) domain which lacks the conserved carboxylate residues of the EGF type B domain. (5) exon f-an activation domain, within which factor XIa cleaves twice, converting factor IX to IXa; (6) exons g and h-the serine protease or catalytic domain, responsible for the proteolysis of factor X to Xa. This region is homologous to other well studied serine proteases (e.g. chymotrypsin) and it is thought likely that his (221), asp (269) and ser (365), all participate in the classical catalytic mechanism.
Factor IX is initially synthesised in the liver as a precursor molecule, either 46, 41 or 39 amino acids (it is not known which, although 39 is probable (Pang et al, 1990 )) longer at its Nterminus than the 415-long mature factor IX found in plasma. Processing steps occur in the hepatocyte prior to secretion and sequentially remove the hydrophobic signal peptide and the propeptide. In addition to the y-carboxylation of the 12 N-terminal glutamyl residues carried out by a vitamin K-dependent carboxylase, and the partial /3-hydroxylation of aspartate 64, Nlinked carbohydrate side chains are added at residues 157 and 167 and at least an O-linked carbohydrate at serine 53.
There are 574 patient entries in this third edition of the database compared with 388 patients last year (Giannelli et al, 1991) . Besides point mutants, it includes 50 short (defined as less than 20 nucleotides) deletions or additions or both, made up from 38 deletions, 9 additions and 3 examples involving both additions and deletions. There are also 12 double mutations, 1 triple mutation, 10 inhibitor patients and 3 female haemophiliacs. The list excludes 29 patients with partial or complete gene deletions or more complex rearrangements (Thompson, 1990) . Of the 574 patients studied (see Summary Table) , 278 are unique molecular events, the remainder being repeats. As is well known, many of these repeats occur at CG doublets and involve a CG-TG or CA change. As discussed before (Giannelli et al, 1991) , such mutants are believed to be genuine 'hotspots' for mutation. However it is now becoming clear that the high number of repeat observations at some CG doublets (e.g. 30 examples at 31, 008) are caused, at least in part, by a founder effect. A founder effect is now well established Bottema et al, 1990b) for a mutation at a residue other than CG's {e.g. 27 examples at nucleotide 31,311) and there are many examples in the database of mutations repeating 2, 3 or occasionally 4 times. Most, but probably not all, of these will have a common origin.
A new feature this year is the inclusion of information in die comments section, on new (or de novo) mutations by the UK and German coordinators. In addition, we note whether the mutation occurred in me mother or in the maternal grandfather or grandmother. The German coordinator has also included the age of the parent of the child carrying, or affected by, the mutant gene. Because only the UK and German coordinators list new mutations, and even their data is incomplete, this database cannot yet be usefully analysed for their frequency.
The distribution of mutants according to protein domains and control regions within the gene (see Summary Table) shows that mutations have been detected in all categories listed except the poly (A) site. Remarkably, there are now 11 molecularly unique mutants occurring within a short region of the promoter, and these are invaluable in studying gene regulation (Crossley & Brownlee, 1990) . Missense mutations within exons give valuable information as to the importance of particular amino acid residues. For example, it is reassuring to note that 3 different mutations have been discovered at the active site serine (amino acid 365) as well as 1 at the proposed active site aspartate (amino acid 269), although none is yet known for the proposed active site histidine at amino acid 221. Mutations at 6 of the 12 7 carboxyglutamyl residues have now been detected, confirming their critical role for the function of factor IX.
The second (1991) edition of this data base (Giannelli et al 1991) is now available from the EMBL file server. It can be obtained by sending die command GET HAEMB.DAT to NETSERV@EMBL-HEIDELBERG.DE (Internet address). A documentation file introducing the format used, which differs from this present data base because of restrictions imposed in transmitting data by electronic mail, is obtained by sending GET HAEMB.DOC to the same address. The format used in the 1991 File Server version of the data base is somewhat related to that used for the familiar EMBL nucleic acid sequence data base and should allow easy computer searching for particular features. The new entries in this 1992 edition of the data base will be reformatted and transferred to die EMBL file server during 1992.
The data base was compiled from separate lists updating the previous year's list prepared by coordinators for the different countries as follows:-Giannelli and Green representing the UK, Sweden and Iceland; High and Sommer representing USA; Lillicrap representing Canada; Ludwig and Olek representing Germany; Reitsma representing The Netherlands; Goossens representing France; Yoshioka representing Japan; and Brownlee, die rest of the world and central coordinator. New data or notification of errors or omissions should be sent to the individual country coordinators. This database is available from individual country coordinators on floppy discs written in WordPerfect 5.1 on an IBM PS2 computer. Acceptor splice (g) Green et al (1989) Green, Montandon et al
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